FDA Approves LEQEMBI IQLIK SC Initiation for Alzheimer
Decision brief
Answer first · skim in under a minute
FDA on July 13, 2026 approved LEQEMBI IQLIK SC initiation (500 mg weekly as two 250 mg shots) for early Alzheimer's; U.S. launch late August 2026.
Key questions this brief answers
- What initiation dose did FDA approve for LEQEMBI IQLIK?
- Can LEQEMBI IQLIK also be used for maintenance?
- When will initiation dosing launch in the U.S.?
FDA LEQEMBI IQLIK initiation subcutaneous approval lets Eisai and Biogen offer at-home autoinjector dosing from the start of early Alzheimer's treatment. The companies said on July 13, 2026 that FDA cleared a 500 mg once-weekly initiation regimen, with U.S. launch planned for late August 2026.
Contents9 sections
Key Takeaways
- FDA approved LEQEMBI IQLIK (lecanemab-irmb) SC autoinjector as an initiation dose for early Alzheimer's.
- Initiation regimen: 500 mg once weekly as two 250 mg injections (~15 seconds each).
- Maintenance option remains 360 mg once weekly after 18 months of IV or SC therapy.
- U.S. initiation-dose launch planned for late August 2026 via specialty pharmacy.
LEQEMBI IQLIK at a glance
| Field | Detail |
|---|---|
| Product | LEQEMBI IQLIK (lecanemab-irmb) subcutaneous autoinjector |
| Companies | Eisai Co., Ltd. and Biogen Inc. |
| FDA action | sBLA approval for initiation dosing announced July 13, 2026 |
| Initiation dose | 500 mg once weekly (two 250 mg injections) |
| Maintenance dose | 360 mg once weekly after 18 months IV or SC |
| Population | Early Alzheimer's (MCI or mild dementia due to AD) |
| U.S. launch | Late August 2026 (company) |
What did the FDA approve?
Eisai and Biogen announced FDA approval of an sBLA for once-weekly lecanemab-irmb subcutaneous injection (LEQEMBI IQLIK) as an initiation dose for early Alzheimer's disease. The companies said this creates a first-of-its-kind anti-amyloid option with at-home dosing for both initiation and maintenance in the U.S.
Full detail is in Eisai's July 13 PR Newswire LEQEMBI IQLIK initiation release.
How is initiation dosing given?
For initiation, the approved regimen is 500 mg once weekly as two 250 mg autoinjector injections. Each injection is delivered in approximately 15 seconds. After 18 months of IV or subcutaneous treatment, LEQEMBI IQLIK may be used for maintenance at 360 mg once weekly. Patients may receive LEQEMBI as IV or SC across the course and may switch between routes.
What clinical evidence supported subcutaneous initiation?
The companies said Clarity AD long-term extension sub-studies showed once-weekly SC administration achieved exposure equivalent to IV dosing, supporting similar clinical and amyloid-biomarker benefits. They said the rate of exposure-related ARIA-E with SC is expected to be comparable to IV, with no increase in isolated ARIA-H versus placebo, and an overall SC safety profile generally similar to IV aside from mostly localized injection-related reactions.
The pivotal Clarity AD program is registered as NCT03887455 on ClinicalTrials.gov. Biogen's public Alzheimer's pipeline materials also describe the lecanemab collaboration; see Biogen's corporate site for company context alongside the wire release.
What about ARIA and other safety warnings?
LEQEMBI carries a boxed warning for amyloid-related imaging abnormalities (ARIA-E and ARIA-H). Serious intracerebral hemorrhage has been observed with this class. ApoE ε4 homozygotes have higher ARIA risk; testing for ApoE ε4 status should be performed before initiation to inform risk. Monitoring and MRI schedules in the approved label still apply whether dosing is IV or SC.
When does initiation dosing launch, and what support exists?
Eisai and Biogen said LEQEMBI IQLIK for initiation dosing is expected to be available in late August 2026 in the U.S., dispensed via specialty pharmacy. Patient support includes the LEQEMBI Companion program for coverage navigation and a Patient Assistance Program for eligible uninsured patients who meet financial criteria.
Related NovaPharma coverage: LEQEMBI subcutaneous maintenance expansion, donanemab early Alzheimer's approval, and other Alzheimer's pipeline updates.
Frequently Asked Questions
What initiation dose did FDA approve for LEQEMBI IQLIK?
Eisai and Biogen said the FDA approved a once-weekly subcutaneous initiation regimen of 500 mg given as two 250 mg autoinjector injections, each delivered in about 15 seconds, for early Alzheimer's disease.
Can LEQEMBI IQLIK also be used for maintenance?
Yes. After 18 months of IV or subcutaneous treatment, LEQEMBI IQLIK may be used for maintenance at 360 mg once weekly. Patients may switch between IV and SC dosing across the treatment course.
When will initiation dosing launch in the U.S.?
Eisai and Biogen said U.S. launch of LEQEMBI IQLIK as an initiation dose is planned for late August 2026, with product supplied through specialty pharmacy.
